The effects of Teneligliptin on vascular inflammatory markers in post-PCI (Percutaneous Coronary Intervention) patients.
- Conditions
- Coronary Artery Disease
- Registration Number
- JPRN-UMIN000027224
- Lead Sponsor
- Kameda Medhical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Not provided
1)Patients with T1DM (type 1 diabetes mellitus) 2)Patients who have medical history of hypersensitivity to diabetes mellitus drugs 3)Patients with medical history of malignant tumor 4)Patients with severe infection, before and after operation, or severe trauma 5)Patients with cardiac arrest (class of III in NYHA) 6)Patients with uncontrolled hypertension 7)Patients with insulin dependent and the potential to change diabetic drugs 8)Patients with severe renal insufficiency (eGFR is less than 30 mL / min / 1.73 m2, dialysis-dependent, or serum creatinine (men, more than 2.5 mg / dL, women, more than 2.0 mg / dL 9) Patients with pregnant, and possibly pregnant 10) Patients with severe ketosis, diabetic coma, or history of coma within the past six months 11)Patients who had stroke, cerebral hemorrhage, subarachnoid hemorrhage, or transient ischemic attack within the past three months. 12)Patients who enrolled into another clinical test within three months prior to this trial 13)Patients who cannot administer antiplatelet drugs 14)Patients who were considered as inappropriate for the study by the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Variation amount and rate of inflammatory markers from pretreatment levels.
- Secondary Outcome Measures
Name Time Method Vascular endothelial function: RH-PAT score, variation amount and rate of HbA1c, and glucose from pretreatment levels.